Home Tags Multiple myeloma

Tag: Multiple myeloma

European Commission Grants Conditional Marketing Authorization to GSK for the Use...

The European Commission has granted conditional marketing authorization* for the use of GlaxoSmithKline's anti-B-cell maturation antigen (BCMA) therapy belantamab mafodotin (Blenrep®) as monotherapy for...

U.S. FDA Approves Belantamab Mafodotin as a Monotherapy in R/R Multiple...

The U.S. Food and Drug Administration has approved* belantamab mafodotin-blmf (Blenrep®; GlaxoSmithKline/GSK) as a monotherapy treatment for adult patients with relapsed or refractory multiple...
Featured Image: Better times - ASCO | McCormick Place. Courtesy: © 2017 Fotolia. Used with permission.

ASCO 2020 – Advancing Antibody-drug Conjugates: Belantamab Mafodotin

Multiple myeloma is the third most common blood cancer and is generally considered treatable, but not curable. Research into new therapies is needed as...

Belantamab Mafodotin Receives Priority Review for Relapsed or Refractory Multiple Myeloma

The United States Food and Drug Administration (FDA) has granted a priority review of a Biologics License Application (BLA) for belantamab mafodotin (GSK2857916), a...

DREAMM-2 Trial Shows Positive Results for Belantamab Mafodotin in Multiple Myeloma

Earlier today positive headline results from the pivotal DREAMM-2 open-label, randomized study of two doses of belantamab mafodotin (GSK2857916), an anti-BCMA antibody-drug conjugate or...
The sign I Amsterdam in front of rijksmuseum in Amsterdam, The Netherlands.

Sutro Presents Preliminary Results From Ongoing Phase I Study of STRO-001

California-based Sutro Biopharma has confirmed that the company will present preliminary results from the first 14 patients enrolled in the company's ongoing Phase I...
Featured Image: Laboratory Glass works. Courtesy: © 2010 - 2018. Fotolia Used with permission.

Sutro Partners with The Leukemia & Lymphoma Society to Develop STRO-001

Earlier today Sutro Biopharma, a clinical-stage drug discovery, development and manufacturing company, and The Leukemia & Lymphoma Society®, the world's largest voluntary health agency...

First Clinical Trial of STRO-001 Targeting CD74 to Treat Lymphoma and...

Researchers have begun dosing patients in its initial clinical trial of a new generation of precisely engineered - first-in-class - antibody-drug conjugate, or ADC,...

New Phase I Study with SGN-CD48A in Relapsed or Refractory Multiple...

Multiple myeloma is an incurable hematologic malignancy formed by malignant or transformed plasma cells in which the cancerous plasma cells can crowd out healthy...

Promising Preclinical Results Show Antibody Effectively Targets CD74 in Lymphoma and...

Two studies presented at the annual meeting of the American Society of Hematology (ASH), held December 9 - 12, 2017, showed frequent expression of...